<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129099</url>
  </required_header>
  <id_info>
    <org_study_id>PGC0006</org_study_id>
    <nct_id>NCT04129099</nct_id>
  </id_info>
  <brief_title>A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL</brief_title>
  <official_title>A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Yanda Ludaopei Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gracell Biotechnology Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Lu Daopei Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Yanda Ludaopei Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an early, open, single-centered trial. The aim of this study is to evaluate the&#xD;
      safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The&#xD;
      study will include 18 subjects to receive GC022F therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment related Adverse Events, CRS and Neurotoxicity (Safety and tolerability)</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events(AEs) will be collected and graded according to ASTCT consensus(for Cytokine Release Syndrome, CRS and Immune Effector Cell-Associated Neurotoxicity Syndrome, ICANS) and CTCAE v5.0(for AE except CRS/ICANS )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAR copies and concentration of GC022F in peripheral blood, bone marrow and CSF (amplification and persistence)</measure>
    <time_frame>2 years</time_frame>
    <description>GC022F CAR copies and cells in peripheral blood, bone marrow and CSF will be measured by qPCR and FCM in 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate of patients who received GC022F infusion (efficacy)</measure>
    <time_frame>2 years</time_frame>
    <description>Overall response rate will be estimated as the percents of patients who achieved CR or CRi.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentraiton of anti-GC022F antibody after infusion (humoral immune response)</measure>
    <time_frame>2 years</time_frame>
    <description>After GC022F infusion, GC022F antibody in peripheral blood will be measured in 2 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>CAR-T treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive one dose of GC022F. GC022F dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC022F</intervention_name>
    <description>GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.</description>
    <arm_group_label>CAR-T treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 2-70 years;&#xD;
&#xD;
          2. Eastern cooperative oncology group (ECOG) performance status of 0 to 2;&#xD;
&#xD;
          3. Life expectancy≥12 weeks;&#xD;
&#xD;
          4. CD19 and/or CD22 tumor expression demonstrated in bone marrow or peripheral blood by&#xD;
             flow cytometry;&#xD;
&#xD;
          5. Relapsed or refractory B- ALL: a) Refractory B- ALL: MRD≥0.1% or fail to achieve a CR&#xD;
             after 2 cycles of a standard induction chemotherapy regimen or one-line/multi-line&#xD;
             salvage chemotherapy; b) Relapsed B- ALL: Relapse after remission for the first time&#xD;
             in 12 months or relapse after one-line/multi-line salvage chemotherapy; Relapse is&#xD;
             defined as MRD≥0.1% or recurrence of primitive cell in peripheral blood or bone&#xD;
             marrow(&gt;5%) after remission; c)Relapse after autologous stem cell transplantation or&#xD;
             allogeneic hematopoietic stem cell transplantation; Relapse is defined as above;&#xD;
             d)Patients with Philadelphia chromosome positive(Ph+) ALL were eligible if they were&#xD;
             intolerant to or had failed two lines of tyrosine kinase inhibitor (TKI) therapy, or&#xD;
             had t315i mutation.&#xD;
&#xD;
          6. Did not receive hematopoietic stem cell transplantation≤6 months prior to enrollment;&#xD;
&#xD;
          7. Adequate organ function defined as: a) Creatinine clearance (as estimated by Cockcroft&#xD;
             Gault) &gt;60 mL/min; b) Serum ALT/AST &lt;2.5 ULN; c) Total bilirubin &lt;1.5 ULN (subjects&#xD;
             with Gilbert's syndrome≤3 ULN); d) Cardiac ejection fraction≥50%, no evidence of&#xD;
             clinically significant pericardial effusion as determined by an ECHO; e) No clinically&#xD;
             significant pleural effusion; f) Baseline oxygen saturation &gt;92% on room air;&#xD;
&#xD;
          8. Females of reproductive age must be in non-lactation period. Females of childbearing&#xD;
             potential must have a negative serum or urine pregnancy test. All subjects must use&#xD;
             medical-approved-contraception (such as intrauterine device and contraceptive drugs)&#xD;
             during the period of trial and in 2 years after cell transfusion therapy; Males should&#xD;
             avoid sperm donation;&#xD;
&#xD;
          9. Venous access can be established, peripheral blood mononuclear cells (PBMC) can be&#xD;
             collected in researcher's judgement;&#xD;
&#xD;
         10. The subject agrees to and sign informed consent form, willing and able to comply with&#xD;
             the planned visit, research, treatment planning, laboratory and other test procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Isolated extra-medullary disease relapse;&#xD;
&#xD;
          2. Central nervous system leukemia involved CNS-3;&#xD;
&#xD;
          3. Concomitant malignancy other than cured non-melanoma skin cancer or cervical carcinoma&#xD;
             in situ or localized prostate cancer or superficial bladder cancer or ductal carcinoma&#xD;
             in situ or diagnosis of other malignancy exceeds 5 years without relapse or treatment&#xD;
             during the 5 years;&#xD;
&#xD;
          4. Any result of the following virology tests is positive: HIV; HCV; HBsAg; or HBCAb&#xD;
             positive with HBV DNA copies positive; TPPA;&#xD;
&#xD;
          5. Live vaccine ≤4 weeks prior to enrollment;&#xD;
&#xD;
          6. For Ph+ ALL, TKI therapy ≤1 weeks prior to enrollment;&#xD;
&#xD;
          7. Presence of ≥ grade 2 acute graft-versus-host disease (GVHD, Glucksberg criteria) or&#xD;
             extensive chronic GVHD (Seattle criteria) that require treatment ≤4 weeks prior to&#xD;
             enrollment, or during the study period the subject is required to receive anti- GCHD&#xD;
             therapy in researcher's judgement;&#xD;
&#xD;
          8. Presence of concomitant disease that require systemic steroids or other immune&#xD;
             suppressive therapy during the study period in researcher's judgement;&#xD;
&#xD;
          9. Allogeneic cell therapy (such as donor lymphocyte infusion, DLI) ≤4 weeks prior to&#xD;
             enrollment;&#xD;
&#xD;
         10. CNS stereotactic radiotherapy ≤4 weeks prior to enrollment;&#xD;
&#xD;
         11. Toxicities related to previous therapy did not relieved to ≤1 grade, except&#xD;
             hematological toxicity and alopecia;&#xD;
&#xD;
         12. Known life-threatening hypersensitivity to cyclophosphamide or fludarabine, or&#xD;
             presence of other intolerant conditions, or severe allergic constitution;&#xD;
&#xD;
         13. Patients with active autoimmune disease (e.g., systemic lupus erythematosus, sjogren&#xD;
             syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel&#xD;
             disease, Hashimoto's thyroiditis, hypothyroidism which can be controlled by thyroid&#xD;
             hormone replacement therapy is an exception);&#xD;
&#xD;
         14. For patients that underwent or plan to undergo major surgical operation before CAR-T&#xD;
             treatment, surgical operation happened ≤4 weeks prior to enrollment, or did not be&#xD;
             fully recovered and clinically stable prior to enrollment, or be anticipated to&#xD;
             undergo major surgical operation during the study;&#xD;
&#xD;
         15. Any unstable cardiovascular diseases happened ≤6 months prior to enrollment, including&#xD;
             but not limited to, unstable angina, myocardial infarction, heart failure (NYHA grade≥&#xD;
             III grade), severe arrhythmia that require drug interference, cardiac&#xD;
             angioplasty/coronary stent implantation/ cardiac bypass surgery ≤6 months prior to&#xD;
             enrollment;&#xD;
&#xD;
         16. Presence of central nervous system(CNS) disease or disease history, including&#xD;
             epilepsy, cerebral Ischemia/bleeding, dementia, cerebellar disease, any autoimmune&#xD;
             diseases that involve CNS;&#xD;
&#xD;
         17. Presence of active infection that require therapy ≤2 weeks prior to apheresis;&#xD;
&#xD;
         18. Any other conditions that researcher think it is inappropriate for the subject to&#xD;
             anticipate the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junfang Yang, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junfang Yang, Bachelor</last_name>
    <phone>13522084342</phone>
    <email>Yangjunfang77@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hebei Yanda Ludaopei Hospital</name>
      <address>
        <city>Sanhe</city>
        <state>Hebei</state>
        <zip>065200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peihua Lu, PhD&amp;MD</last_name>
      <phone>+86-0316-3306393</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

